{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T17:38:17Z","timestamp":1771522697854,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013105","name":"Shanghai Rising-Star Program","doi-asserted-by":"publisher","award":["24YF2704300"],"award-info":[{"award-number":["24YF2704300"]}],"id":[{"id":"10.13039\/501100013105","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203403"],"award-info":[{"award-number":["82203403"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81702507"],"award-info":[{"award-number":["81702507"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203150"],"award-info":[{"award-number":["82203150"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.intimp.2026.116186","type":"journal-article","created":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T04:49:17Z","timestamp":1768711757000},"page":"116186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Adjuvant bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy versus BCG combined with disitamab vedotin in BCG-na\u00efve high-risk non-muscle invasive bladder cancer with HER2 expression: A real-world study"],"prefix":"10.1016","volume":"172","author":[{"given":"Tianyuan","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wentao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danjing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingcheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xudong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.116186_bb0005","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder Cancer (TaT1 and carcinoma in situ)-a summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.intimp.2026.116186_bb0010","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.euo.2023.10.003","article-title":"Prognostic significance of HER2 expression in patients with Bacillus Calmette-Guerin-exposed non-muscle-invasive bladder Cancer","volume":"7","author":"Tan","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.intimp.2026.116186_bb0015","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJMp1615697","article-title":"Ensuring access to injectable generic drugs - the case of Intravesical BCG for bladder Cancer","volume":"376","author":"Davies","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.116186_bb0020","doi-asserted-by":"crossref","DOI":"10.1002\/bco2.70034","article-title":"Real-world oncological and toxicity outcomes with the Moscow strain of intravesical BCG for non-muscle invasive bladder cancer-implications for global shortage","volume":"6","author":"Arora","year":"2025","journal-title":"BJUI Compass"},{"key":"10.1016\/j.intimp.2026.116186_bb0025","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrurol.2015.58","article-title":"Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer","volume":"12","author":"Kamat","year":"2015","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.intimp.2026.116186_bb0030","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/iju.14761","article-title":"Outcomes of bacillus Calmette-Guerin therapy without a maintenance schedule for high-risk non-muscle-invasive bladder cancer in the second transurethral resection era","volume":"29","author":"Kikuchi","year":"2022","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.intimp.2026.116186_bb0035","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2026.116186_bb0040","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S1470-2045(24)00178-5","article-title":"Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial","volume":"25","author":"Necchi","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2026.116186_bb0045","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in untreated advanced urothelial Cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.116186_bb0050","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of Disitamab Vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.116186_bb0055","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.annonc.2024.12.002","article-title":"Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib\/II dose-escalation and dose-expansion study","volume":"36","author":"Zhou","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2026.116186_bb0060","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1186\/s12885-025-14154-4","article-title":"RC48-ADC monotherapy or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma with HER2 low and null expression: a multicenter, real-world, retrospective study","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.intimp.2026.116186_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102085","article-title":"Disitamab Vedotin alone or in combination with immune checkpoint inhibitors in bladder-sparing treatment of muscle-invasive bladder Cancer: a real-world study","volume":"22","author":"Wang","year":"2024","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.intimp.2026.116186_bb0070","doi-asserted-by":"crossref","DOI":"10.1002\/imt2.70033","article-title":"Efficacy and biomarker analysis of neoadjuvant disitamab vedotin (RC48-ADC) combined immunotherapy in patients with muscle-invasive bladder cancer: a multi-center real-world study","volume":"4","author":"Hu","year":"2025","journal-title":"Imeta"},{"key":"10.1016\/j.intimp.2026.116186_bb0075","article-title":"Lin T (2025) Intravesical Disitamab Vedotin (RC48) for HER2-expressing high-risk non-muscle-invasive bladder Cancer: a single-arm, Dose-Escalation Phase I Trial Study","volume":"6","author":"Chen","year":"2020","journal-title":"MedComm"},{"issue":"5S","key":"10.1016\/j.intimp.2026.116186_bb0080","doi-asserted-by":"crossref","DOI":"10.1097\/01.JU.0001109848.08748.9e.09","article-title":"PD12-09 preliminary efficacy and safety of disitamab vedotin (DV) combined with bacillus calmette-gurin (BCG) in the treatment of high-risk non-muscle invasive bladder cancer with her2 expression: a prospective, open label, single-center study","volume":"213","author":"Shen","year":"2025","journal-title":"J. Urol."},{"key":"10.1016\/j.intimp.2026.116186_bb0085","article-title":"Zeng H (2025) efficacy of Disitamab Vedotin and immune profiles in high-risk non-muscle-invasive bladder Cancer with HER2 overexpression","volume":"6","author":"Liu","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.intimp.2026.116186_bb0090","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1565859","article-title":"Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells","volume":"8","author":"Bauzon","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2026.116186_bb0095","first-page":"1001","article-title":"Clinical pathological expert consensus on HER-2 testing in urothelial carcinoma in China","volume":"43","author":"Tumor Pathology Committee of Chinese Anti-Cancer A, Expert Committee on Urothelial Carcinoma of Chinese Society of Clinical O","year":"2021","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"10.1016\/j.intimp.2026.116186_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2025.03.007","article-title":"Oncological outcomes in Bacillus Calmette-Guerin-naive high-risk non-muscle-invasive bladder Cancer patients: a systematic review on current treatment strategies and future perspectives","author":"Longoni","year":"2025","journal-title":"Eur Urol Oncol."},{"key":"10.1016\/j.intimp.2026.116186_bb0105","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer--a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.intimp.2026.116186_bb0110","article-title":"Modified Glasgow prognostic score as a predictor of recurrence in patients with high grade non-muscle invasive bladder Cancer undergoing Intravesical Bacillus Calmette-Guerin immunotherapy","volume":"12","author":"Ferro","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.intimp.2026.116186_bb0115","doi-asserted-by":"crossref","first-page":"189 e181","DOI":"10.1016\/j.urolonc.2024.11.015","article-title":"Impact of smoking exposure on disease progression in high risk and very high-risk nonmuscle invasive bladder cancer patients undergoing BCG therapy","volume":"43","author":"Contieri","year":"2025","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.intimp.2026.116186_bb0120","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00345-024-05392-5","article-title":"PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG","volume":"43","author":"de Jong","year":"2025","journal-title":"World. J. Urol."},{"key":"10.1016\/j.intimp.2026.116186_bb0125","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1158\/1078-0432.CCR-19-1920","article-title":"Adaptive immune resistance to Intravesical BCG in non-muscle invasive bladder Cancer: implications for prospective BCG-unresponsive trials","volume":"26","author":"Kates","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116186_bb0130","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41420-025-02489-7","article-title":"Heightened IDO1 levels predict Bacillus Calmette-Guerin failure in high-risk non-muscle-invasive bladder cancer patients","volume":"11","author":"Turdo","year":"2025","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.intimp.2026.116186_bb0135","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1134\/S0006297920100156","article-title":"The role of ERBB2\/HER2 tyrosine kinase receptor in the regulation of cell death","volume":"85","author":"Daks","year":"2020","journal-title":"Biochemistry (Mosc)"},{"key":"10.1016\/j.intimp.2026.116186_bb0140","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/s41556-019-0352-z","article-title":"HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity","volume":"21","author":"Wu","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.intimp.2026.116186_bb0145","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13046-025-03454-z","article-title":"Single-cell transcriptome analysis reveals the malignant characteristics of tumour cells and the immunosuppressive landscape in HER2-positive inflammatory breast cancer","volume":"44","author":"Huang","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116186_bb0150","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41419-023-06073-8","article-title":"A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway","volume":"14","author":"Wu","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2026.116186_bb0155","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder Cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification Systems for Grade: An update from the EAU NMIBC guidelines panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur. Urol."},{"key":"10.1016\/j.intimp.2026.116186_bb0160","doi-asserted-by":"crossref","first-page":"180","DOI":"10.23736\/S2724-6051.22.04953-9","article-title":"Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCG","volume":"75","author":"Contieri","year":"2023","journal-title":"Minerva Urol Nephrol"},{"key":"10.1016\/j.intimp.2026.116186_bb0165","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.euo.2023.07.012","article-title":"Oncological outcomes for patients with European Association of Urology very high-risk non-muscle-invasive bladder Cancer treated with Bacillus Calmette-Guerin or early radical cystectomy","volume":"6","author":"Contieri","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.intimp.2026.116186_bb0170","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.euo.2024.01.017","article-title":"Unlocking the potential of adequate Bacillus Calmette-Guerin immunotherapy in very-high-risk non-muscle-invasive bladder carcinoma: a multicenter analysis of oncological outcomes and risk dynamics","volume":"7","author":"Subiela","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.intimp.2026.116186_bb0175","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1097\/JU.0000000000001943","article-title":"Progression of disease after Bacillus Calmette-Guerin therapy: refining patient selection for neoadjuvant chemotherapy before radical cystectomy","volume":"206","author":"Hensley","year":"2021","journal-title":"J. Urol."},{"key":"10.1016\/j.intimp.2026.116186_bb0180","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.juro.2010.02.026","article-title":"The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade ta, T1 and CIS bladder cancer","volume":"183","author":"Guevara","year":"2010","journal-title":"J. Urol."},{"key":"10.1016\/j.intimp.2026.116186_bb0185","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s00345-018-2299-2","article-title":"Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought","volume":"36","author":"Palou","year":"2018","journal-title":"World. J. Urol."},{"key":"10.1016\/j.intimp.2026.116186_bb0190","doi-asserted-by":"crossref","first-page":"490 e413","DOI":"10.1016\/j.urolonc.2022.05.016","article-title":"Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer","volume":"40","author":"Ferro","year":"2022","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.intimp.2026.116186_bb0195","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1158\/1078-0432.CCR-24-3321","article-title":"Phase II pilot trial of Tislelizumab plus low-dose nab-paclitaxel for extensive very high-risk non-muscle-invasive bladder Cancer","volume":"31","author":"Qie","year":"2025","journal-title":"Clin. Cancer Res."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926000299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926000299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T16:57:43Z","timestamp":1771520263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926000299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":39,"alternative-id":["S1567576926000299"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116186","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy versus BCG combined with disitamab vedotin in BCG-na\u00efve high-risk non-muscle invasive bladder cancer with HER2 expression: A real-world study","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116186","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116186"}}